| 样本编号 | SAMC6561314 |
|---|---|
| 外部数据库编号 | GSA-Human: HRS2101849 |
| 样品名称 | Proteosome_S2B |
| 样本标题 | S2B_Bort |
| 样品类型 | Human sample |
| 物种名称 | Homo sapiens |
| 描述信息 | Human T cells were isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors, activated with CD3/CD28 beads, and then transduced with a CD19 CAR construct. Five days later, the CAR T cells were treated with 0.1nM Bortezomib for 48 hours. Subsequently, CD19 CAR live cells were sorted and subjected to single-cell RNA sequencing (scRNA-seq). |
| 样本属性 | *该样本包含更多受控访问信息，请通过GSA-Human系统申请项目HRA014168数据获取。 |
| 发布日期 | 2026-01-25 |
| 项目编号 | PRJCA048991 |
| 提交者 | Yingxi Xu (xuyingxi@ihcams.ac.cn) |
| 提交单位 | Peking Union Medical College |
| 提交日期 | 2026-01-09 |
| 资源名称 | 描述 |
|---|---|
| GSA-Human (1) | - |
| HRA014168 (Controlled Access) | Our previous data showed that CAR T cells with high proteasome activity exhibit reduced therapeutic efficacy due to their tendency to undergo terminal differentiation. And pre-treatment of CAR T cells during manufacturing with a low dose of bortezomib significantly improved their anti-tumor efficacy. To investigate how short-term bortezomib treatment prolongs the survival of leukemia-bearing mice, we performed single-cell multi-omics (scMulti-omics) analysis. |